A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
CNBX Pharmaceuticals Inc.
CNBX
$55K
Mkt Cap
$0.00
+0.00%
CNBX Pharmaceuticals Inc. (CNBX) has a 5-year average return on invested capital (ROIC) of -160.3%. This is below average and may indicate limited pricing power.
CNBX Pharmaceuticals Inc. (CNBX) has a market capitalization of $87K. It is classified as a small-cap stock.
CNBX Pharmaceuticals Inc. (CNBX) does not currently pay a regular dividend.
CNBX Pharmaceuticals Inc. (CNBX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
CNBX Pharmaceuticals Inc. (CNBX) generated $-171 thousand in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
The Ledger Terminal provides 11 years of financial data for CNBX Pharmaceuticals Inc. (CNBX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CNBX Pharmaceuticals Inc. (CNBX) has a book value per share of $-0.00, based on its most recent annual SEC filing.
CNBX PHARMACEUTICALS, INC. is based in Bethesda, Maryland, is a clinical stage company dedicated to discovery, development and commercialization of novel cannabinoid-based products and innovative technologies for the treatment of cancer. Our first lead product candidate is a Cannabics SR, the oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome (CACS). Our leading anti-neoplastic drug candidate under development for Colorectal Cancer (CRC) is RCC-33. Historically we were previously an exploration stage mining company which transitioned into a bio-tech company in 2014. Our corporate address is #3 Bethesda Metro Center, Suite 700, Bethesda, Maryland, 20814; Telephone (877) 424-2429. The Company was previously engaged in the oil and gas exploration business.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - | 0 |
| Net Income | -393K | -314K | -695K | -3.7M | -3.7M | -3.2M |
| EPS | $-0.02 | $-0.00 | $-0.02 | $-0.42 | $-3.59 | $-2.40 |
| Free Cash Flow | -180K | -171K | -245K | -113K | -1.7M | -2.5M |
| ROIC | -2115.2% | -1164.2% | -802.6% | -179.2% | -141.4% | -264.4% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -0.96 | -1.04 | -1.33 | -2.15 | 0.97 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -299K | -272K | -583K | -931K | -3.0M | -2.6M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | - | - | - | - | -176.9% |
| Shares Outstanding | 871M | 554M | 554M | 31M | 28M | 0M |
| Metric | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | 0 | N/A | N/A | N/A | N/A | N/A | 0 | N/A | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | 139K | 178K | 1.0M | 1.0M | 1.5M | 1.7M | 1.8M | 1.2M | 432K | 195K | 0 | 0 |
| SG&A | 334K | 215K | 1.3M | 2.4M | 1.5M | 1.3M | 829K | 1.8M | 910K | 518K | 272K | 299K |
| EBIT | -537K | -281K | -3.8M | -3.8M | -3.3M | -3.0M | -2.6M | -3.0M | -931K | -583K | -272K | -299K |
| Op. Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -541K | -1.6M | -1.9M | -3.8M | 1.1M | -7.5M | -3.2M | -3.7M | -3.7M | -695K | -314K | -393K |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -89K | 0 | 0 |
| Returns on Capital | ||||||||||||
| ROIC | N/M | N/M | -102.4% | -113.7% | -21.8% | -136.3% | N/M | -141.4% | -179.2% | N/M | N/M | N/M |
| ROE | -26.2% | N/A | -65.8% | -142.8% | N/A | -423.2% | -176.9% | N/A | N/A | N/A | N/A | 0.0% |
| ROA | -23.8% | -6688.8% | -53.2% | -118.6% | 7.5% | -336.5% | -103.8% | -459.0% | -743.5% | -2215.2% | -1260.4% | -3523.9% |
| Cash Flow | ||||||||||||
| Op. Cash Flow | -179K | -120K | -864K | -2.0M | 3.1M | -2.8M | -2.5M | -1.7M | -113K | -244K | -171K | -180K |
| Free Cash Flow | -182K | -120K | -1.8M | -2.9M | 2.9M | -2.9M | -2.5M | -1.7M | -113K | -245K | -171K | -180K |
| Owner Earnings | -180K | -122K | -2.8M | -2.1M | 2.7M | -3.1M | -2.7M | -2.6M | -455K | -456K | -171K | -180K |
| CapEx | 3K | 0 | 942K | 942K | 217K | 76K | 0 | 2K | 0 | 1K | 0 | 0 |
| Maint. CapEx | 1K | 2K | 88K | 88K | 189K | 215K | 221K | 199K | 162K | 72K | 0 | 0 |
| Growth CapEx | 2K | N/A | 854K | 854K | 28K | 0 | 0 | 0 | N/A | 0 | N/A | 0 |
| D&A | 1K | 2K | 88K | 88K | 189K | 215K | 221K | 199K | 162K | 72K | 0 | 0 |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | ||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | N/A | N/A | 1.9M | N/A | 247K | 72K | 34K | 729K | 180K | 140K | 0 | 0 |
| Debt Repayment | 0 | 0 | 22K | 22K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||||||||
| Net Debt | N/A | N/A | N/A | N/A | N/A | N/A | -1.0M | 3.3M | 2.4M | 2.5M | 2.4M | 2.4M |
| Cash & Equiv. | 25K | 19K | 3.4M | 1.4M | 266K | 778K | 1.4M | 118K | 130K | 26K | 15K | 15K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 2.4M |
| Debt/Equity | -1.09 | -1.05 | 0.24 | 0.20 | N/A | 0.26 | 0.97 | -2.15 | -1.33 | -1.04 | -0.96 | 0.00 |
| Interest Coverage | -177.3 | -39.1 | -4470.3 | N/A | -180.1 | -374.2 | -1087.5 | -2320.5 | -793.3 | -30.2 | -6.8 | -6.8 |
| Equity | -310K | -467K | 2.9M | 2.6M | N/A | 1.8M | 1.8M | -1.6M | -2.0M | -2.5M | -2.5M | -2.6M |
| Total Assets | 29K | 24K | 3.6M | 3.2M | 15M | 2.2M | 3.1M | 811K | 499K | 31K | 18K | 11K |
| Total Liabilities | 338K | 491K | 699K | 539K | N/A | 455K | 1.3M | 2.4M | 2.5M | 2.5M | 2.5M | 46K |
| Intangibles | 0 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -1.3M | -1.6M | -3.5M | -7.3M | -6.2M | -14M | -17M | -21M | -24M | -25M | -25M | -25M |
| Working Capital | -313K | -469K | 2.8M | 1.1M | 3.9M | 475K | 318K | -2.2M | -2.3M | -2.5M | -2.5M | -2.6M |
| Current Assets | 26K | 22K | 3.5M | 1.6M | 4.3M | 930K | 1.6M | 198K | 224K | 31K | 18K | 11K |
| Current Liabilities | 338K | 491K | 699K | 539K | 439K | 455K | 1.3M | 2.4M | 2.5M | 2.5M | 2.5M | 2.6M |
| Per Share Data | ||||||||||||
| EPS | -1.20 | -0.36 | -2.16 | -3.72 | 2.40 | -12.00 | -2.40 | -3.59 | -0.42 | -0.02 | -0.00 | -0.02 |
| Owner EPS | -0.40 | -0.12 | -3.13 | -2.03 | 2.36 | -4.92 | -262.11 | -0.09 | -0.01 | -0.00 | -0.00 | -0.00 |
| Book Value | -0.69 | -0.47 | 3.28 | 2.61 | N/A | 2.84 | 172.28 | -0.06 | -0.06 | -0.00 | -0.00 | -0.00 |
| Cash Flow/Share | -0.40 | -0.12 | -0.96 | -1.95 | 2.75 | -4.46 | -237.81 | -0.06 | -0.00 | -0.00 | -0.00 | -0.00 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 0.5M | 1.0M | 0.9M | 1.0M | 1.1M | 0.6M | 0.0M | 28.3M | 31.1M | 554.0M | 554.0M | 870.8M |
| Valuation | ||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | 13.5 | N/A | N/A | N/A | N/A | N/A | N/A | -0.0 |
| P/FCF | N/A | N/A | N/A | N/A | 12.7 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 36.9 | 42.1 | N/A | 8.2 | 14.6 | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -1.9% | -2.2% | -1.7% | -2.6% | 18.8% | -19.6% | -9.5% | -1.7% | -27.2% | -6.8% | -61.8% | -206.3% |
| Market Cap | 9.7M | 5.5M | 109M | 111M | 15M | 15M | 26M | 96M | 414K | 3.6M | 277K | 87K |
| Avg. Price | 29.96 | 7.83 | 144.34 | 130.32 | 52.14 | 28.15 | 28.04 | 10.75 | 1.31 | 0.01 | 0.01 | 0.00 |
| Year-End Price | 21.60 | 5.48 | 121.20 | 109.80 | 32.40 | 23.34 | 19.80 | 3.40 | 0.01 | 0.01 | 0.00 | 0.00 |
CNBX Pharmaceuticals Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
No recent press releases.